SRR650131
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.480
- INTERFERON_GAMMA_RESPONSE+0.380
- SPERMATOGENESIS+0.340
- E2F_TARGETS+0.310
- KRAS_SIGNALING_DN+0.310
- G2M_CHECKPOINT+0.260
- ALLOGRAFT_REJECTION+0.210
- PANCREAS_BETA_CELLS+0.200
- INFLAMMATORY_RESPONSE+0.140
- IL6_JAK_STAT3_SIGNALING+0.130
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.560
- TGF_BETA_SIGNALING-0.440
- P53_PATHWAY-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- ADIPOGENESIS-0.370
- DNA_REPAIR-0.370
- HYPOXIA-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- FATTY_ACID_METABOLISM-0.340
- MYC_TARGETS_V2-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_FX2P2WEG | high-grade glioma | — | 0.837 |
| 2 | SRR25617831 | — | D | 0.837 |
| 3 | C3L-02654 | — | cohortA1 | 0.809 |
| 4 | TCGA-55-A4DF-01A-11R-A24H-07 | — | cohortA3 | 0.804 |
| 5 | ERR2208907 | — | — | 0.800 |
| 6 | SRR10899995 | — | — | 0.793 |
| 7 | AUR-AG0J-TTP1-A-1-0-R-A741-41 | — | D | 0.793 |
| 8 | AUR-AD9G-TTP1-B-4-0-R-A584-39 | — | D | 0.792 |
| 9 | SRR1516037 | — | — | 0.785 |
| 10 | TCGA-P3-A5QE-01A-11R-A28V-07 | — | — | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.340 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |